Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Mar 1:282:258-260.
doi: 10.1016/j.jad.2020.12.069. Epub 2020 Dec 24.

Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?

Anees Bahji  1 , Gustavo H Vazquez  2 , Carlos A Zarate Jr  3
Affiliations
Comment

Response to commentary on the comparative efficacy of esketamine vs. ketamine meta-analysis: Putting the cart before the horse?

Anees Bahji et al. J Affect Disord. .
No abstract available

PubMed Disclaimer

Comment on

References

    1. Bahji A, Ermacora D, Stephenson C, Hawken ER, Vazquez G, 2020a. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis. J. Affect. Disord 269, 154–184. 10.1016/j.jad.2020.03.030. - DOI - PubMed
    1. Bahji A, Ermacora D, Stephenson C, Hawken ER, Vazquez G, 2020b. Comparative efficacy and tolerability of adjunctive pharmacotherapies for acute bipolar depression: a systematic review and network meta-analysis: Efficacité Et Tolérabilité comparatives des Pharmacothérapies D’appoint Pour La Dépression Bipolaire Aiguë: Une Revue Systématique Et Une Méta-Analyse De Réseau. Can. J. Psychiatry Rev. Can. Psychiatry, 706743720970857 10.1177/0706743720970857. - DOI - PMC - PubMed
    1. Bahji A, Vazquez GH, Zarate CA, 2020c. Comparative efficacy of racemic ketamine and esketamine for depression: a systematic review and meta-analysis. J. Affect. Disord 12473. 10.1016/j.jad.2020.09.071. - DOI - PMC - PubMed
    1. Chaki S, 2018. Is metabolism of (R)-ketamine essential for the antidepressant effects? Int. J. Neuropsychopharmacol 21, 154–156. 10.1093/ijnp/pyx120. - DOI - PMC - PubMed
    1. Correia-Melo FS, Leal GC, Carvalho MS, Jesus-Nunes AP, Ferreira CBN, Vieira F, Magnavita G, Vale LAS, Mello RP, Nakahira C, Argolo FC, Cardoso T, Souza CDS, Fontes ATC, Ferreira MB, Araújo-de-Freitas L, Tuena MA, Echegaray MVF, Cavalcanti DE, Lucchese AC, Bandeira ID, Telles M, Lima CS, Sampaio AS, Silva SS, Marback RF, Del-Porto JA, Abreu JN, Sarin LM, Paixão CS, Carvalho LP, Machado PRL, Turecki G, Lacerda ALT, Quarantini LC, 2018. Comparative study of esketamine and racemic ketamine in treatment-resistant depression: protocol for a non-inferiority clinical trial. Med. (Baltimore) 97, e12414. 10.1097/MD.0000000000012414. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources